Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
Rhea-AI Summary
Elicio Therapeutics (Nasdaq: ELTX) announced that CEO Robert Connelly and CSO Pete DeMuth will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, in New York. The session is scheduled for Monday, September 14, 2026, at 2:00 PM ET, with a live webcast and 90-day replay available via Elicio’s Events page. Interested attendees can request 1×1 meetings with management through their H.C. Wainwright representative.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 24 | Conference participation | Neutral | -2.0% | Management announced one-on-one meetings at the Wells Fargo healthcare conference. |
| Aug 13 | Second-quarter earnings | Negative | -1.9% | Phase 2 trial missed its primary endpoint despite additional clinical updates. |
| Aug 10 | Phase 1 trial activation | Positive | -2.8% | Investigator-initiated neoadjuvant study of ELI-002 7P was activated. |
| Jul 06 | Registered direct offering | Negative | -15.0% | Registered direct offering closed with approximately $15 million in gross proceeds. |
| Jul 02 | Offering pricing | Negative | -37.4% | Company priced a registered direct offering of 4,380,313 common shares. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news events were followed by negative 24-hour reactions, with the largest declines occurring after offering announcements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that Robert Connelly, Chief Executive Officer and Pete DeMuth, PhD, Chief Scientific Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York, New York.
H.C. Wainwright 28th Annual Global Investment Conference
Format: Fireside Chat
Date: Monday, September 14, 2026
Time: 2:00 PM ET
The live webcast and replay of the presentation will be available here and on Elicio’s Events page for 90 days following the event.
If you are interested in arranging a 1×1 meeting with management at the conference, please contact your H.C. Wainwright representative.
About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing next-generation immunotherapies for the treatment of KRAS-driven cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical findings in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s AMP technology aims to enhance the education, activation, and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 7P lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drive approximately
Investor Relations Contact
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
